Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04579380|
Recruitment Status : Recruiting
First Posted : October 8, 2020
Last Update Posted : March 2, 2021
This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial have either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable).
All participants will get both tucatinib and trastuzumab. People with hormone-receptor positive breast cancer will also get a drug called fulvestrant.
The trial will also look at what side effects happen. A side effect is anything a drug does besides treating cancer.
|Condition or disease||Intervention/treatment||Phase|
|Uterine Neoplasms Uterine Cervical Neoplasms Biliary Tract Neoplasms Urologic Neoplasms Carcinoma, Non-Small-Cell Lung Breast Neoplasms||Drug: tucatinib Drug: trastuzumab Drug: fulvestrant||Phase 2|
There are multiple cohorts in this trial:
- 5 tumor specific cohorts with HER2 overexpression/amplification (cervical cancer, uterine cancer, biliary tract cancer, urothelial cancer, and non-squamous non-small cell lung cancer [NSCLC])
- 2 tumor specific cohorts with HER2 mutations (non-squamous NSCLC and breast cancer)
- 2 cohorts which will enroll all other HER2 amplified/overexpressed solid tumor types (except breast cancer, GEC, and CRC) or HER2-mutated solid tumor types.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||270 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations|
|Actual Study Start Date :||January 11, 2021|
|Estimated Primary Completion Date :||January 31, 2023|
|Estimated Study Completion Date :||May 31, 2025|
Experimental: Tucatinib + Trastuzumab (+ Fulvestrant)
Tucatinib + trastuzumab (+ fulvestrant in hormone-receptor positive HER2-mutant breast cancer only)
300 mg orally twice daily
Other Name: TUKYSA, ARRY-380, ONT-380
Given into the vein (intravenously; IV). 8mg/kg IV on Cycle 1 Day 1, and 6mg/kg every 21 days starting on Cycle 2 Day 1
Other Name: Herceptin
Given into the muscle (intramuscular; IM) once every 4 weeks starting from Cycle 1 Day 1, plus one dose on Cycle 1 Day 15. Only administered to participants with hormone-receptor positive breast cancer.
Other Name: Faslodex
- Confirmed objective response rate (cORR) per investigator assessment [ Time Frame: From start of treatment up to approximately 2 years ]cORR is defined as the proportion of participants with best overall response of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
- Disease control rate (DCR) per investigator assessment [ Time Frame: From start of treatment up to approximately 2 years ]DCR is defined as the proportion of participants with confirmed CR, confirmed PR, or stable disease according to RECIST v1.1
- Duration of response (DOR) per investigator assessment [ Time Frame: From start of treatment up to approximately 2 years ]DOR is defined as the time from first documentation of objective response of confirmed CR or confirmed PR to the first documentation of disease progression per RECIST v1.1 or death from any cause, whichever occurs first.
- Progression-free survival (PFS) per investigator assessment [ Time Frame: From start of treatment up to approximately 2 years ]PFS is defined as the time from the date of treatment initiation to the date of disease progression according to RECIST v1.1 or death from any cause, whichever occurs first.
- Overall survival (OS) [ Time Frame: From start of treatment up to approximately 4 years ]OS is defined as the time from treatlemt initiation to death due to any cause.
- Incidence of adverse events (AEs) [ Time Frame: From start of treatment up to approximately 2 years ]
- Incidence of laboratory abnormalities [ Time Frame: From start of treatment up to approximately 2 years ]
- Incidence of dose alterations [ Time Frame: From start of treatment up to approximately 2 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04579380
|Contact: Seagen Trial Information Supportemail@example.com|
|United States, Arizona|
|Arizona Oncology Associates, PC - HAL||Recruiting|
|Phoenix, Arizona, United States, 85016|
|United States, California|
|Pacific Shores Medical Group||Recruiting|
|Long Beach, California, United States, 90813|
|United States, Minnesota|
|Saint Louis Park, Minnesota, United States, 55416|
|Principal Investigator: Daniel Anderson|
|United States, North Carolina|
|Duke University Medical Center||Recruiting|
|Durham, North Carolina, United States, 27710|
|Principal Investigator: Thomas Stinchcombe|
|United States, Tennessee|
|Tennessee Oncology-Nashville/Sarah Cannon Research Institute||Recruiting|
|Nashville, Tennessee, United States, 37203|
|Principal Investigator: Erika Hamilton|
|United States, Virginia|
|Virginia Cancer Specialists, PC||Recruiting|
|Fairfax, Virginia, United States, 22031|
|Principal Investigator: Alexander Spira|
|United States, Washington|
|Northwest Cancer Specialists, P.C.||Recruiting|
|Vancouver, Washington, United States, 98684|
|Study Director:||Vicky Kang, MD||Seagen Inc.|